Fig. 3: Treatment-effect estimates derived from experimental arm vs concurrent control arm or hybrid control arm. | Communications Medicine

Fig. 3: Treatment-effect estimates derived from experimental arm vs concurrent control arm or hybrid control arm.

From: Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer

Fig. 3

Treatment efficacy was assessed via (A) DCR, (B) PFS, and (C) OS endpoints comparing the MORPHEUS experimental arm (atezolizumab + isatuximab) to the concurrent-control arm or the hybrid-control arm (regorafenib), separately. CC concurrent control, DCR disease control rate, EC external control, HC hybrid control, HR hazard ratio, OR odds ratio, OS overall survival, PFS progression-free survival, SMRW Standardized mortality ratio weighting.

Back to article page